ALCLS pivots to in vivo gene editing; first data planned for 2027
The company says it is pivoting toward in vivo gene editing with two lead assets for severe lipid disorders and expects first-in-human trial data in 2027. It also cites preclinical efficacy/specificity and a cash runway into H2 2028.